WD Pharmaceutical
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech company developing proprietary drug/device delivery platforms (UGi-Pump® and AcuSiS®) to improve drug absorption and administration for challenging patient populations.
Neurology (Parkinson's Disease)CardiovascularInfectious Disease
Technology Platform
Two proprietary drug/device combination platforms: UGi-Pump® for upper gastrointestinal retention and controlled release, and AcuSiS® for pediatric/geriatric drug delivery to address swallowing difficulties.
Opportunities
Opportunities include expanding its platform technologies beyond Parkinson's disease into its listed cardiovascular and infectious disease areas, and forming licensing or co-development partnerships with larger pharma companies seeking improved formulations for challenging APIs.
Risk Factors
Key risks are technical and regulatory challenges associated with novel drug/device combination products, competition from other drug delivery companies, and dependence on securing additional funding to advance its undisclosed pipeline through clinical trials.
Competitive Landscape
Competes with other drug delivery technology firms (e.g., Adare Pharma Solutions, Assertio Holdings' specialty portfolio) and neurology-focused biotechs. Differentiation is its specific focus on upper GI retention and pediatric/geriatric administration challenges.